Bexaroten- kapsler evalueredes ved kliniske forsøg omfattende 193 CTCL- patienter, hvoraf 93 havde sygdommen på et fremskredet stadium og var resistente over for tidligere, systemisk behandling.
8 Bexarotene capsules were evaluated in clinical trials of 193 patients with CTCL of whom 93 had advanced stage disease refractory to prior systemic therapy.